Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma

Table 1 Baseline characteristics of enrolled patients

Patient	Diagnosis and stage^*	Age (years)	Gender	Extranodal involvements	IPI score	Previous treatments			Response assessment^† at enrollment	Deauville score^† at enrollment (5-point scale)	Preconditioning
Patient	Diagnosis and stage^*	Age (years)	Gender	Extranodal involvements	IPI score	Lines of treatment	RT	Targeted theray	Response assessment^† at enrollment	Deauville score^† at enrollment (5-point scale)	Preconditioning
P1	ALCL, IIIB	23	Male	No	2	2	No	Brentuximab	SD	4	BEAM
P2	NS HL, IIA	30	Male	Lung	1	4	Yes	Anti-PD-1 mAb	PD	5	BEAM
P3	MC HL, IVA	26	Female	No	3	6	Yes	Anti-PD-1 mAb, CAR30 T-cell therapy	PR	5	BEAM
P4	NS HL, IIA	18	Female	No	1	4	No	Anti-PD-1 mAb	PD	4	BEAMF
P5	NS HL, IVB	25	Male	Lung	2	7	Yes	Anti-PD-1 mAb	PD	5	BEAMF
P6	NS HL, IIIA	20	Male	Skin, muscles	2	4	Yes	Anti-PD-1 mAb	SD	5	BEAM

^*According to Ann Arbor staging.
^†According to Lugano criteria for response assessment (PET/CT-based) in lymphoma
IPI international prognostic index, RT radiation therapy, ALCL anaplastic large-cell lymphoma, NS HL nodular sclerosis Hodgkin lymphoma, MC HL mixed cellularity Hodgkin lymphoma, mAb monoclonal antibody, SD stable disease, PD progressive disease, PR partial remission, BEAM bis-carmusitine, etoposide, cytarabine and melphalan, P patient, F fludarabine

ISSN: 2162-3619